Congenital diaphragmatic hernia as a potential target for transamniotic stem cell therapy

Area of Science:

• Regenerative Medicine
• Developmental Biology
• Fetal Surgery

Background:

• Congenital diaphragmatic hernia (CDH) is a severe birth defect with significant respiratory implications.
• Current prenatal interventions for CDH are limited, necessitating novel therapeutic approaches.
• Amniotic fluid-derived mesenchymal stem cells (afMSCs) offer potential for regenerative therapies.

Purpose of the Study:

• To investigate the impact of transamniotic stem cell therapy (TRASCET) on experimental fetal CDH.
• To evaluate the effects of TRASCET on key lung development gene expressions in a CDH model.

Main Methods:

• A nitrofen-induced CDH model was established in pregnant dams.
• Fetal CDH was treated with intra-amniotic afMSCs (TRASCET) or saline on gestational day 17.
• Gene expression of FGF-10, VEGF-A, and SPC was quantified via qRT-PCR in fetal lungs.

Main Results:

• TRASCET significantly downregulated FGF-10 and VEGF-A expressions in surviving CDH fetuses compared to untreated and saline groups.
• Surfactant protein-C (SPC) expression was elevated in the TRASCET group versus the untreated group.
• Lung laterality did not significantly influence these gene expression changes.

Conclusions:

• Transamniotic stem cell therapy modulates critical lung development pathways in experimental CDH.
• TRASCET demonstrates potential as a novel prenatal therapeutic strategy for CDH.
• Further research is warranted to explore TRASCET's role in prenatal CDH management.